Compare Samsara Inc (IOT) vs Oscar Health Inc (OSCR) Price & Performance

Samsara Inc. (IOT) trades at $41.61, up 2.72% today, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $0.20 exceeding the $0.16 forecast. Revenue growth is robust, projected to rise from $1.25 billion in 2025 to $1.8 billion in 2026, while the company transitions to profitability with a net margin of 4.9% in 2026. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion.

The investment outlook is positive, driven by earnings beats, revenue acceleration, and a consensus price target of $51.15 implying 23% upside. However, high valuation multiples (P/E of 274.8, P/S of 13.01) pose risks if growth slows. Cash flow pressures in 2026 and insider selling are additional concerns. The stock's momentum depends on sustaining its growth trajectory amid competitive and execution risks.

OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.

The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.